{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009202","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.836609+00:00","generated_at":"2026-06-17T21:35:56.232585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Surrozen reports FY2022 net loss of $36M; cash runway into H2 2024","bullets":["Net loss for FY2022 was $36.0M vs $54.6M in FY2021; collaboration revenue $12.5M from Boehringer Ingelheim deal.","Cash, equivalents and marketable securities $75.8M as of Dec 31, 2022, down from $123.5M a year ago.","Restructuring reduces operating expenses by ~15% in 2023; cash runway extends into second half of 2024.","SZN-043 Ph1a enrolled first chronic liver disease patient, data expected end 2023; SZN-1326 Ph1a to reinitiate mid-2023.","Repurchased 5.38M shares and 1.31M warrants from Consonance for ~$2.7M; Consonance no longer holds shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009202","json":"https://secwatch.observer/filing/0000950170-23-009202.json","markdown":"https://secwatch.observer/filing/0000950170-23-009202.md","text":"https://secwatch.observer/filing/0000950170-23-009202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/srzn-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:35:56.232585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"801517d1d8bd0a30cce6063b32252a90cff90be3","claim":"Surrozen, Inc./DE reported the year ended December 31, 2022 results: revenue $12.5 million.","evidence_excerpt":"Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$12.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"adba4c5a8b69ca0c88b1a919454eb386a7f3c6ef","claim":"Surrozen, Inc./DE reported the fourth quarter ended December 31, 2022 results: revenue $12.5 million.","evidence_excerpt":"Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$12.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}